Thoracic re-irradiation has a high risk of severe adverse events, and re-irradiation with curative intent has rarely been performed. However, in recent years, with the introduction of intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy, it has become possible to deliver high doses to the target lesions while minimizing the doses to surrounding tissues. The patient in this case had a history of definitive radiation therapy for esophageal cancer. The patient developed new lung cancer, which was treated by re-irradiation. We created a radiation treatment plan using IMRT. This allowed us to reduce the dose to organs at risk and deliver a higher dose to the cancer, increasing the potential for cure. The patient has not experienced any severe late adverse events as of three years and six months after treatment. Additionally, the treatment has been sufficiently effective, and the patient remains recurrence-free. To confirm the feasibility of the IMRT plan, we also created a radiation treatment plan using three-dimensional conformal radiation therapy (3D-CRT) and compared it with the IMRT plan. Compared with 3D-CRT, the IMRT plan was able to reduce the dose to organs at risk and meet the dose constraints indicated in multiple studies. The possibility of adverse events such as bronchial hemorrhage, esophageal hemorrhage, bronchial fistula, radiation pneumonitis, esophageal fistula, and pericarditis was significantly reduced.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11562875PMC
http://dx.doi.org/10.7759/cureus.71540DOI Listing

Publication Analysis

Top Keywords

radiation therapy
24
adverse events
12
imrt plan
12
radiation
9
thoracic re-irradiation
8
created radiation
8
radiation treatment
8
treatment plan
8
reduce dose
8
dose organs
8

Similar Publications

Background: Breast cancer is one of the most common cancers, increasingly prevalent also among working-age populations. Regardless of age, breast cancer has significant direct and indirect costs on the individuals, families and society. The aim of the research was to provide a comprehensive bibliometric analysis of the financial toxicity of breast cancer, to identify research voids and future research challenges.

View Article and Find Full Text PDF

Introduction: Leukemic stemcells (LSC) are the source of relapse in acute myeloid leukemia (AML). Thus,eliminating LSC is one of the overarching goals of AML research. Radioimmunotherapyis an immunotherapeutic approach which utilizes radioactive isotopes aseffector molecules based on the proven ability of ionizing radiation (IR) tokill LSC.

View Article and Find Full Text PDF

Objectives: The aim of this study was to investigate the role of lymph node yield (LNY), lymph node ratio (LNR), and neutrophil to lymphocyte ratio (NLR) as prognostic factors, their impact on survival in patients with advanced laryngeal squamous cell carcinoma (LSCC).

Methods: This multicentric retrospective study included 195 patients with clinical N0 advanced laryngeal carcinoma who underwent total laryngectomy and/or total pharyngolaryngectomy over 5 years. The number of lymph nodes extracted (LNY) and the number of positive nodes were counted.

View Article and Find Full Text PDF

Intradermal Incobotulinum Toxin A for Postbreast Cancer Treatment Asymmetry: A Literature Review and Case Report.

J Cosmet Dermatol

January 2025

Ophthalmologist - Oculoplastic Surgery, Sociedad Internacional de Rejuvenecimiento Facial no Quirurgico (SIRF), Barranquilla, Colombia.

Background: Botulinum toxin (BTX) is globally the most common aesthetic procedure. Its usage has expanded beyond facial treatments to therapeutic areas, including managing scars and postsurgical deformities. Breast cancer survivors often face significant deformities and asymmetry during recovery.

View Article and Find Full Text PDF

Emerging Novel Combined CAR-NK Cell Therapies in Cancer Treatment: Finding a Dancing Partner.

Mol Ther

January 2025

Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of California, Irvine, CA; Chao Family Comprehensive Cancer Center, University of California, Irvine, CA. Electronic address:

In recent decades, immunotherapy with chimeric antigen receptors (CAR) has revolutionized cancer treatment and given hope where other cancer therapies have failed. CAR-NK cells are NK cells that have been engineered ex vivo with a CAR on the cell membrane with high specificity for specific target antigens of tumor cells. The impressive results of several studies suggest that CAR-NK cell therapy has significant potential and successful performance in cancer treatment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!